Navigation Links
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Date:12/7/2008

(39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), pain in limb and abdominal pain (each 15%), bone pain (14%), back pain and hypotension (each 13%), herpes zoster, nasopharyngitis, upper respiratory tract infection, myalgia and pneumonia (each 12%), muscle cramps (11%), and dehydration and anxiety (each 10%). Twenty percent (20%) of patients experienced at least 1 episode of greater than or equal to Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

In the Phase 3 VELCADE + melphalan and prednisone study, the safety profile of VELCADE in combination with melphalan/prednisone is consistent with the known safety profiles of both VELCADE and melphalan/prednisone. The most commonly reported adverse events for VELCADE in combination with MP vs MP, respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pa
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  After the February 2014 ... Injury billing solution for medical practices and management ... toward the new software. "The feedback has ... Thompson . "The sheer number of demos and new ... need was for these types of software features." ...
(Date:8/27/2014)... 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) has ... (FDA) to initiate a Phase 1/2a clinical trial of ... cord injury.  The approved trial follows the successful completion ... and is designed to assess safety and activity of ... spinal cord injuries, the first targeted indication for AST-OPC1 ...
(Date:8/26/2014)... -- Intelomed is pleased to announce that Mary ... the Vice President of Clinical Affairs. With over 30 ... industry, Kay,s experience in taking medical technology and associated ... global expansion, is a valuable addition to the Intelomed ... our team, and I am confident her focused and ...
Breaking Medicine Technology:Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2
(Date:8/27/2014)... Aug. 27, 2014 (HealthDay News) -- A new genetic ... to fight the bowel disorder, researchers report. ... that affect how their genes work, and said these ... with raising the possibility of a simple diagnostic test ... the disease develops and suggest possible gene targets for ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The ... the recipients of the 2014-2016 Basic Research Fellowships and ... career scientists, the ABTA is seeding the field with ... change our understanding of the causes, effects, diagnosis and ... by a scientific committee based on the potential to ...
(Date:8/27/2014)... According to a new market ... Market (Applications: Cardiovascular, Gynecology, Pain Management, Oncology, Urology, ... - Global Industry Analysis, Size, Share, Growth, Trends ... technologies market was valued at USD 4,698 million ... market worth USD 10,611 million in 2020 at ...
(Date:8/27/2014)... Disability (CLD) has received a two-year, $600,000 grant ... the Health Resources and Services Administration to support ... at improving services for children and youth with ... project, CLD worked with an Autism Advisory Council ... resulting plan addresses priorities of increased awareness of ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Representatives with ... added Italy to its list of destinations for International ... for Recharge Retreats, explained that the company chose Italy ... destination for yoga teacher trainings since it's an easy ... journey for people traveling from all over Europe, UK, ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 2Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 3
... ,KO Cancer, with Susan G. Komen for the Cure, ... boxers,Felix "Tito" Trinidad and Roy Jones Jr. -- who will ... Jan. 19 -- have teamed with Susan G.,Komen for the ... activists, to help educate and raise awareness regarding the,deadly disease., ...
... diagnostic imaging, BLOOMINGTON, Minn., Dec. 21 ... efficiency of care reduced,medical expenses by $74 million ... introduced in February, reduced unnecessary,tests by more than ... from the American College of Radiology to confirm ...
... BROOK, Ill. December 21, 2007 The ... for the role of endoscopy in treating dyspepsia, discomfort ... a fourth of the population in Western countries. ... instrument to evaluate the inside of the esophagus, stomach ...
... for 2007, CONCORD, Ontario, Dec. 21 ... ,OTG, ,the Company,), a,leading multi- industry computer hardware, ... received an order for 100TB SAN dedicated,to pioneering ... oncology hospitals. The EqualLogic iSCSI SAN order is ...
... HLS ) announced today that its Board of Directors ... on its 6.5%,Series A Convertible Perpetual Preferred Stock, payable ... 2, 2008., About HealthSouth, HealthSouth is the ... states across the country and in,Puerto Rico, HealthSouth serves ...
... by Dr. Steve Bailey, an internationally recognized sports historian, ... the beginnings, achievements and events that shaped the Paralympic ... Movement and other able-bodied sports. , In addition ... First establishes key players in administration and sports politics, ...
Cached Medicine News:Health News:Don King Enlists Prizefighters Felix 'Tito' Trinidad and Roy Jones Jr. to Strike a Blow against Breast Cancer 2Health News:Don King Enlists Prizefighters Felix 'Tito' Trinidad and Roy Jones Jr. to Strike a Blow against Breast Cancer 3Health News:HealthPartners Reports 2007 Most Cost Effective Programs Reduce Expenses by $74 Million 2Health News:ASGE offers guidelines on endoscopic treatment of dyspepsia 2Health News:ASGE offers guidelines on endoscopic treatment of dyspepsia 3Health News:On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects 2Health News:On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects 3Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2Health News:First reputable book on the history of the Paralympic Movement 2
The playful pattern of this lens features sky-blue forms fanning out from the center of your eye....
This design features a solid red iris....
Tempting and mesmerizing Jaguar features a narrow black slit surrounded by reflective metallic teal....
Maumenee vitreous aspirating cannula, 18 gauge....
Medicine Products: